Varian, Inc. Reports Fourth Quarter 20...(------------------- ------------------- ...),Health

Date:11/4/2009

------------------- ------------------- October 2, October 3, October 2, October 3, 2009 2008 2009 2008 --------- --------- --------- --------- Cash flows from operating activities Net earnings $ 1,940 $ 20,377 $ 38,620 $ 65,114 Adjustments to reconcile net earnings to net cash provided by operating activities: Depreciation and amortization 6,470 8,128 26,783 29,346 Gain on disposition of property, plant and equipment (90) (22) (230) (474) Impairment of private company equity investment - - - 3,018 Purchased in-process research and development - 215 - 1,703 Share-based compensation expense 1,672 2,466 7,705 9,673 Excess tax benefit from share-based plans (705) (894) (705) (894) Deferred taxes (11,157) (1,251) (12,211) (1,791) Unrealized loss (gain) on currency remeasurement 929 (7,959) 525 (5,286) Changes in assets and liabilities, excluding effects of acquisitions: Accounts receivable, net 1,093 (22,940) 42,387 (12,205) Inventories 12,812 11,618 24,663 (19,428) Prepaid expenses and other current assets 386 2,811 403 3,300 Other assets 1,531 (736) 168 (1,462) Accounts payable 9,260 (2,293) (8,663) (1,072) Deferred profit (1,289) 440 (2,103) (3,526) Accrued liabilities 11,196 10,853 (3,061) 14,053 Other liabilities (490) (1,416) (1,394) (1,048)
'/>"/>

SOURCE Varian, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Related medicine technology :

1. Varian, Inc. to Release Fourth Quarter and Full Fiscal Year 2009 Financial Results
2. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
3. 96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
4. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
5. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
6. Cambrex Reports Third Quarter 2009 Results
7. Regeneron Reports Third Quarter 2009 Financial and Operating Results
8. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
9. Uroplasty Reports Results for Second Quarter FY2010
10. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
11. Mettler-Toledo International Inc. Reports Third Quarter 2009 Results